LENT Prognostic Score (Malignant Pleural Effusion)

LENT sums points for pleural fluid LDH, ECOG performance status, serum NLR, and tumour type. Total range 0–7. Intended for patients presenting with malignant pleural effusion (first episode in derivation cohorts). ECOG reference: performance status scales.

Pleural fluid LDH (IU/L)

>1500 IU/L scores 1 point; ≤1500 scores 0 (per Thorax 2014 Table 3).

ECOG performance status

Serum neutrophil-to-lymphocyte ratio (NLR)

>9 scores 1 point; ≤9 scores 0 (per original publication Table 3).

Tumour type (primary malignancy category)

Disclaimer: The LENT score was derived and validated in cohorts with confirmed malignant pleural effusion. It is a prognostic aid and does not replace clinical judgment, histologic diagnosis, or individualized treatment planning. Median survival figures describe published groups, not guaranteed individual outcomes.

LENT score — scoring guide

Overview

The LENT prognostic score (pleural fluid Lactate dehydrogenase, ECOG performance status, serum Neutrophil-to-lymphocyte ratio, Tumour type) was developed and validated in patients with malignant pleural effusion (MPE). It stratifies overall survival and, in the original report, outperformed ECOG alone for short-term mortality discrimination. Reference: Clive AO et al., Thorax 2014;69(12):1098–1104. DOI 10.1136/thoraxjnl-2014-205285.

Component points

Variable	Criterion	Points
L — LDH (pleural fluid)	≤1500 IU/L vs >1500 IU/L	0 / 1
E — ECOG PS	0 → 0; 1 → 1; 2 → 2; grades 3–4 → 3 (combined row in primary Table 3)	0–3
N — NLR (serum)	Neutrophil count ÷ lymphocyte count; ≤9 vs >9	0 / 1
T — Tumour type	0 pts: mesothelioma, haematological malignancy1 pt: breast, gynaecological, renal cell carcinoma2 pts: lung cancer, other types not in the groups above	0 / 1 / 2

Total score range 0–7. Values exactly at published thresholds (e.g. LDH 1500 IU/L, NLR 9) follow the original table: ≤1500 and ≤9 are the lower-risk cells; strictly >1500 or >9 earn the higher-risk point(s).

Risk groups (UK Cohort 1, primary paper)

Group	Total LENT	Median survival (reported)
Low	0–1	319 days (IQR 228–549)
Moderate	2–4	130 days (IQR 47–467)
High	5–7	44 days (IQR 22–77)

Intended use and limits

Developed in patients with robust MPE diagnoses presenting with a first effusion episode.
May not apply to suspected MPE without confirmation, paramalignant effusions, or incomplete data.
Does not incorporate extent of disease, prior therapy, or recurrent vs new cancer presentation.
Use for prognosis and care planning discussions, not as a standalone treatment rule.

Background and purpose

Malignant pleural effusion (MPE) is a common complication of advanced cancer. It often causes breathlessness, reduces functional capacity, and marks a phase of illness where treatment choices—such as repeated therapeutic aspiration, tunneled pleural catheter, or attempts at pleurodesis—must balance symptom relief, procedural risk, length of hospital stay, and patient goals. Clinicians frequently over- or underestimate short-term survival; a simple, reproducible prognostic index can support shared decision-making and service planning when used as an adjunct to judgment, histology, staging, and comorbidity review.

The LENT prognostic score (Lactate dehydrogenase in pleural fluid, Eastern Cooperative Oncology Group performance status, serum Neutrophil-to-lymphocyte ratio, and Tumour type) was developed to stratify overall survival in unselected patients with MPE using variables that are widely available at initial presentation. It was subsequently validated in an independent cohort. The acronym is a memory aid for the four domains; the total score ranges from 0 to 7, with three risk groups that corresponded to materially different survival experience in the reported data.

Population and timing of assessment

The score is intended for patients with a confirmed malignant pleural effusion, assessed at presentation with the effusion (derivation and validation cohorts captured first episodes of MPE, which could represent a new cancer diagnosis or progression/recurrence of known malignancy). It does not target paramalignant effusions, effusions without cytologic or biopsy-proven malignancy, or settings where the diagnosis remains uncertain. Performance status and laboratory values should reflect the clinical picture at the time the score is calculated; repeating the score after major changes (for example, large-volume drainage, infection, or systemic therapy response) may be reasonable for longitudinal context, but the original publications emphasize baseline stratification rather than dynamic serial modeling.

Score components in detail

L — Pleural fluid lactate dehydrogenase (LDH)

Pleural fluid LDH reflects enzyme release from damaged or metabolically active cells within the pleural space. Higher levels have long been associated with more inflammatory or “active” effusions and, in several series, poorer prognosis in malignant effusions. In the LENT model, pleural fluid LDH is dichotomized at 1500 IU/L: values greater than 1500 contribute one point; values 1500 or lower contribute zero points. Laboratories should report results in the same units (IU/L) used in the original work; if your institution uses different reference methods, interpret thresholds cautiously and in consultation with local laboratory medicine.

E — ECOG performance status

Global functional capacity remains one of the strongest clinical predictors in advanced cancer. The LENT score maps Eastern Cooperative Oncology Group (ECOG) grades to points as follows: ECOG 0 earns 0 points, ECOG 1 earns 1 point, ECOG 2 earns 2 points, and ECOG 3 or 4 each map to 3 points (the highest contribution from any single domain). This stepwise weighting recognizes that even modest restriction (ECOG 1–2) and especially severe limitation (3–4) track with shorter survival in pleural malignancy. When assigning ECOG, use the same pragmatic bedside criteria as in oncology practice: ability to carry out activities of daily living, time spent in bed, and need for care, rather than inferring from laboratory values alone.

N — Serum neutrophil-to-lymphocyte ratio (NLR)

NLR is calculated as the absolute neutrophil count divided by the absolute lymphocyte count from a peripheral blood sample. It is an inexpensive marker of systemic inflammatory tone that has been linked to outcomes across multiple solid tumours. In LENT, NLR greater than 9 adds one point; 9 or lower adds zero. Acute intercurrent illness (infection, glucocorticoid exposure, marrow stress) can shift neutrophil and lymphocyte counts; where possible, interpret NLR in clinical context and avoid over-weighting a single spurious value drawn during unrelated acute physiology.

T — Tumour type (primary category)

Underlying histology or clinical tumour category is incorporated as a three-tier assignment. Lowest-risk types (0 points) in the published schema are mesothelioma and haematological malignancy. Moderate-risk types (1 point) include breast cancer, gynaecological cancers, and renal cell carcinoma. Highest-risk types (2 points) are lung cancer and an “other” group that captures malignancies not listed in the lower tiers—examples in broader pleural oncology practice include gastrointestinal primaries, melanoma, sarcoma, urological cancers, and some unknown-primary presentations, subject to how the effusion was classified in the source data. The tumour component encodes the wide dispersion of median survival observed across cell types in international cohorts prior to score construction.

Total score and risk groups

Points from all four domains are summed. The theoretical range is 0–7. For interpretation, patients are grouped as:

Low risk: total score 0–1
Moderate risk: total score 2–4
High risk: total score 5–7

In the primary development cohort, reported median overall survival differed sharply across these bands: approximately 319 days for low risk, 130 days for moderate risk, and 44 days for high risk, with interquartile ranges illustrating substantial within-group variability. Short-term survival proportions also diverged: high-risk patients had materially lower observed survival at one, three, and six months compared with low-risk patients. These figures describe group-level experience; they must not be read as fixed individual predictions.

Discrimination and comparison with ECOG alone

Receiver operating characteristic analyses in the original work indicated that the composite LENT score achieved higher area under the curve values than ECOG performance status alone for mortality at one, three, and six months in the development set, with similar patterns demonstrated in the validation cohort for later time points. A summary concordance index (C statistic) in the reported range of roughly 0.71–0.75 across cohorts suggests moderate overall discrimination for death—typical for clinically parsimonious bedside scores. The score’s particular strength, as emphasized by the authors, lies in identifying a subgroup with very limited short-term survival who may wish to avoid prolonged inpatient interventions.

How clinicians can use the score responsibly

Practical uses include: framing prognosis discussions with patients and families; aligning intensity of invasive pleural procedures with anticipated benefit and preferred place of care; informing multidisciplinary tumour board conversations; and enriching eligibility or stratification discussions for clinical trials in MPE, where ensuring participants can survive long enough to reach endpoints is essential. The score should not be used to deny symptom-directed care, to replace histologic diagnosis, or to override patient values. It is also not a substitute for assessing reversible contributors to dyspnoea (airway disease, pulmonary embolism, anemia, cardiac comorbidity) or for specialist pleural evaluation when diagnosis is incomplete.

Limitations and generalizability

Several constraints deserve emphasis. The derivation cohorts reflected real-world case mix but included centre-specific distributions—particularly a higher proportion of mesothelioma in some regions—which may differ from other hospitals; sensitivity analyses suggested robustness when mesothelioma-heavy subsets were considered, yet local tumour biology still matters. The score does not encode extent of disease, prior lines of therapy, molecular subtype, or whether the effusion represented new diagnosis versus progression—factors that can dominate outcomes for certain cancers. Missing data were handled with rigorous methods in the research setting; at the bedside, incomplete pleural fluid studies or absent differential counts limit applicability. Finally, contemporary systemic and immune therapies have evolved since initial publication; calibration may shift over time even if the relative ranking of risk groups remains informative.

Practical documentation checklist

Confirm MPE using cytology, biopsy, or accepted institutional criteria consistent with the score’s intent.
Record pleural fluid LDH (IU/L) from the diagnostic sample when feasible.
Assign ECOG using standard oncology definitions at the time of assessment.
Use a recent CBC for NLR; repeat if skewed by acute reversible factors when decisions are not urgent.
Classify tumour type using the LENT three-tier scheme; when histology is pending, avoid over-interpretation until category is clear.

CalcMD.

LENT Prognostic Score for Malignant Pleural Effusion

Learn the LENT prognostic score for malignant pleural effusion: pleural fluid LDH, ECOG, serum NLR, and tumour type (0–7), risk groups, survival context, and safe clinical use.